A randomized, placebo-controlled trial of deoxynucleotide and pegylated interferon α-2a in treatment of chronic hepatitis B(CHB﹚ with abnormal liver function
- VernacularTitle:脱氧核苷酸联合聚乙二醇化干扰素α-2a治疗慢性乙型病毒性肝炎合并肝功能异常随机安慰剂对照的临床研究
- Author:
Yan LUO
1
;
Xiaoran LI
;
Jin HE
;
Xiaohui JIANG
;
Lei HAO
Author Information
1. 贵州省第一人民医院感染科
- Keywords:
Deoxynucleotides;
Interferon;
Viral hepatitis;
Abnormal liver function
- From:
China Modern Doctor
2015;(2):27-29
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy of deoxynucleotide combined with pegylated interferon α-2a in the treatment of chronic hepatitis B (CHB﹚ with liver injury. Methods All 92 cases of CHB with liver injury patients were selected in our clinical study. All patients were randomly divided into treatment group(n=46, treated with PEG-IFNα-2a and deoxynucleotide acid injection, 200 mg/d, intravenous drip﹚and control group (n=46, treated with PEG-IFNα-2a﹚.Then assessment of CHB serum markers and liver function after 48 weeks continuous treatment. Results There were significant differences between the two groups in the HBV-DNA negative rate (60.7% v s 39.2%﹚, the HBeAg se roconversion rate (34.8%vs 15.2%﹚, the HBsAg negative rate (28.3% vs 10.8%﹚, the ALT levels(51.6±12.4 vs 72.3± 15.3﹚U/L, the AST levels(51.8±12.8 vs 70.8±13.4﹚U/L, the TBiL levels(23.5±7.6 vs 33.4±6.8﹚μmol/L, the ALP lev-els(87.2±24.2 vs 158.4±28.7﹚U/L, the serum levels of total protein (76.2±9.2 vs 65.2±8.2﹚g/L, albumin (37.5±8.3 vs 32.3±7.9﹚g/L, and the A/G levels (1.8±0.3 vs 1.4±0.3﹚(P<0.05﹚. What’s more, during the course of treatment, the neutropenia rate(6.5%vs 26.1%﹚,thrombocytopenia incidence rate (4.3% vs 23.9%﹚also had significant difference be-tween the treatment group and control group (P<0.05﹚. Conclusion There is synergistic clinical efficacy of deoxynu-cleotide combined pegylated interferonα-2a, and less adverse events during treatment.
